Pharmacists in Sikeston, Missouri


28 Pharmacists found in Sikeston
female pharmacist

Dr. Kristen Ann Komaiko, PHARMD


Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
808 E Wakefield Ave, Sikeston, MO 63801
573-471-1930    

female pharmacist

Dr. Layal Al Labban


Pharmacist
1213 Huntress Dr, Sikeston, MO 63801
313-460-3580    

female pharmacist

Lindsey Ballard Corlew, PHARM D


Pharmacist
808 Hunter Ave, Suite 1, Sikeston, MO 63801
573-472-0608     573-472-1814



female pharmacist

Dr. Lindsey Bauer


Pharmacist
808 Hunter Ave, Ste. 1a, Sikeston, MO 63801
573-475-1900     573-472-1814

male pharmacist

Luke Joseph Dobbelare, PHARMD


Pharmacist
1303 S Main St, Sikeston, MO 63801
573-471-6775    

female pharmacist

Marcia Diane Buescher


Pharmacist
1303 S Main St, Sikeston, MO 63801
573-471-6775    

male pharmacist

Dr. Matthew Scott Hon, PHARM. D.


Pharmacist - Pharmacotherapy
808 Hunter Ave Ste 1, Sikeston, MO 63801
573-475-1900     573-472-1814

male pharmacist

Mr. Ronnie Wade Hamra, RPH


Pharmacist
507 N Main St, Sikeston, MO 63801
573-471-4401     573-471-5448

male pharmacist

Dr. Ross Merideth, PHARM D


Pharmacist
808 Hunter Ave, Ste. 1a, Sikeston, MO 63801
573-475-1900     573-472-1814

female pharmacist

Dr. Sandra T Bollinger, PHARMD, CGP, CDE


Pharmacist
808 E Wakefield Ave, Sikeston, MO 63801
573-471-1930     573-471-4591

male pharmacist

Thomas M Tullis, R.PH.


Pharmacist
299 N Main St, Sikeston, MO 63801
573-471-7048     573-471-2806

male pharmacist

Dr. Zachary Gerard Smith, PHARMD


Pharmacist
1303 S Main St, Sikeston, MO 63801
573-471-6775    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.